Cemotherapi Induce Alopecia Due Carboplatin-Paclitaxel Regiment
September 2024
in “
International Journal of Advanced Multidisciplinary Research and Studies
”
This study conducted at Dr. Moewardi Surakarta Hospital focused on the adverse drug reactions, specifically alopecia, associated with the carboplatin-paclitaxel chemotherapy regimen, which is commonly prescribed for cervical, breast, and ovarian cancers. Using a cross-sectional design, the research included adult cancer patients undergoing this treatment. The findings revealed that alopecia was the most prevalent adverse reaction, affecting 100% of the participants. The severity of alopecia was assessed using the Common Terminology Criteria for Adverse Events (CTCAE), with all cases classified at grade 2 severity.